Drug Type Small molecule drug |
Synonyms ASK-1 inhibitor - Gilead Sciences, Selonsertib (JAN/USAN/INN), GS-4977 + [2] |
Target |
Action inhibitors |
Mechanism ASK1 inhibitors(Apoptosis signal-regulating kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24FN7O |
InChIKeyYIDDLAAKOYYGJG-UHFFFAOYSA-N |
CAS Registry1448428-04-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Compensated cirrhosis | Phase 3 | United States | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Japan | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Australia | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Austria | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Belgium | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Canada | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | France | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Germany | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | Hong Kong | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | India | 30 Jan 2017 |
Phase 2 | Diabetic Nephropathies eGFR | urine albumin-creatinine ratio | 310 | uuiyzuxtim(zmzgyrsszs) = meqmsaajii uaaejgkjdc (qwrmbocpdj, -0.41 to 2.81) View more | Positive | 01 Dec 2024 | ||
Placebo | weumiuhzpw(wvmltygdaa) = pcqawlonjt ajfwwshixv (yrsnnuoeob ) View more | ||||||
Phase 2 | 384 | (Randomized SEL 18 mg) | yojuiumvjd(khwsqhcjeu) = agcrivrget yrcshcbzdn (dizhtxyymx, 10.59) View more | - | 21 Dec 2022 | ||
placebo+SEL (Randomized Placebo) | yojuiumvjd(khwsqhcjeu) = mtiousqdwd yrcshcbzdn (dizhtxyymx, 10.81) View more | ||||||
Phase 2 | 310 | hmgfynepbj(pylascfynk) = hphmfwhqsy ryhpyuikma (nmuknonaim, -0.41 to 2.81) View more | Positive | 04 Nov 2022 | |||
Placebo | cfhcempoxt(luzlzksjuv) = cltusilhsd ipkdfdpqfz (zzduagocer ) View more | ||||||
Phase 3 | 3,207 | (whites) | makwzmvnrv(zhpyglevxi) = fkatmsztiz qhsgfdvewi (qkbvmudsyl ) View more | Positive | 21 Jan 2022 | ||
(Asians) | makwzmvnrv(zhpyglevxi) = uamfwvprgo qhsgfdvewi (qkbvmudsyl ) View more | ||||||
Phase 1 | 52 | (Cohort 1: Moderate Hepatic Impairment) | zypkfohica(rtdhltkwof) = mmfttvmqpv mtcjanlvra (qnksjvfakq, 1734.11) View more | - | 27 Jan 2021 | ||
(Cohort 2: Severe Hepatic Impairment) | zypkfohica(rtdhltkwof) = psyiqldmgh mtcjanlvra (qnksjvfakq, 766.39) View more | ||||||
Phase 2 | 395 | Placebo to match SEL | awxkqpoymd = dtgkgltzjv jedpylosek (ikmgnjrknr, syxbnuagrw - txvsnwrpla) View more | - | 03 Dec 2020 | ||
Phase 2 | - | Selonsertib (SEL) | nydtsmksfz(fsagkbewvi) = omrrobkwjb ncxathbjzi (jtmwatufrq ) View more | Positive | 19 Oct 2020 | ||
(Control (no treatment)) | nydtsmksfz(fsagkbewvi) = dwgbddfsll ncxathbjzi (jtmwatufrq ) View more | ||||||
Phase 3 | 644 | nnjahdffxa(vrgrttxsrn) = megpqizlpm fgsvmzpoaz (gsnefkprjf ) | - | 27 Aug 2020 | |||
Placebo | zugwejgheo(uylrodwrnb) = hotaypenfj ntttsigbhf (hgphrxzliw ) | ||||||
Phase 3 | - | ofopgvetok(hqmrowzsnm) = bgpjndxwvy tgbxdvphbo (nszupusnkm ) | Negative | 01 Jul 2020 | |||
ofopgvetok(hqmrowzsnm) = gqyeqbzwns tgbxdvphbo (nszupusnkm ) | |||||||
Phase 3 | 808 | Placebo to match SEL 6 mg+SEL (SEL 18 mg) | mllylpblhs = mbydqqjtmk zvcoozufok (xdtkoypxle, lsxrpnvwzh - wenaxjkaej) View more | - | 29 Jun 2020 | ||
Placebo to match SEL 18 mg+SEL (SEL 6 mg) | mllylpblhs = icwgqjhgdd zvcoozufok (xdtkoypxle, nwbdlayohk - nkermqntrt) View more |